A Clean Fight: Comparing Metronidazole and Silver Sulfadiazine Gels in Treating Infected Diabetic Foot Ulcers: A Randomized Control Trial

Background: Diabetic foot ulcers (DFUs) are a major cause of morbidity and non-traumatic amputations among patients with diabetes. Infection delays healing and increases the risk of severe complications, underscoring the need for effective topical treatments. Objective: To compare the efficacy of topical Metronidazole versus Silver Sulfadiazine (SSD) in promoting wound healing in infected DFUs, and to evaluate the influence of systemic markers, including HbA1c, CRP, and albumin, on treatment outcomes. Methods: This randomized, double-blind controlled trial was conducted at the Centre Médical de Saint-Jean-sur-Veyle from April to June 2025. Ninety adult patients with mild-to-moderate infected DFUs were randomly assigned to either Metronidazole or SSD. Patients with severe infection, osteomyelitis, or severe ischemia were excluded. Participants received daily topical application of either 1% Metronidazole or 1% SSD gel for four weeks, alongside standard care including debridement, offloading, and glycemic control. The primary outcome was complete wound healing at 4 weeks. Secondary outcomes included wound size reduction, time to healing, and changes in infection severity scores. Subgroup analyses assessed the impact of clinical covariates on healing. Results: Among 90 participants, 86 completed the trial. The Metronidazole group had a significantly higher healing rate (86.7%) compared with the SSD group (68.9%; p = 0.011). ANCOVA showed a significant treatment effect on wound size (F = 6.89; p = 0.011). GEE analysis identified a significant time-by-treatment interaction (OR = 3.06; p = 0.002). Poor healing was associated with wound size ≥5 cm², HbA1c ≥8%, CRP ≥10 mg/L, and albumin <3.5 g/dL. Conclusions and Relevance: Metronidazole was more effective than SSD in promoting short-term wound healing in infected DFUs. It may be considered a preferred topical agent, especially in settings with high anaerobic burden and limited resources.

Authors

Institutions

Publication Details

Journal
Java Nursing Journal
Published
2025-09-30
DOI
https://doi.org/10.61716/jnj.v3i3.115
Primary Topic
Diabetic Foot Ulcer Assessment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Clean Fight: Comparing Metronidazole and Silver Sulfadiazine Gels in Treating Infected Diabetic Foot Ulcers: A Randomized Control Trial

Giulia Romano, Élodie Garnier, Claire More, Asmat Burhan et al.
Java Nursing Journal
Diabetic Foot Ulcer Assessment and Management
article

A Clean Fight: Comparing Metronidazole and Silver Sulfadiazine Gels in Treating Infected Diabetic Foot Ulcers: A Randomized Control Trial

Giulia Romano, Élodie Garnier, Claire More, Asmat Burhan, Lara Navarro
article en

Abstract

Background: Diabetic foot ulcers (DFUs) are a major cause of morbidity and non-traumatic amputations among patients with diabetes. Infection delays healing and increases the risk of severe complications, underscoring the need for effective topical treatments. Objective: To compare the efficacy of topical Metronidazole versus Silver Sulfadiazine (SSD) in promoting wound healing in infected DFUs, and to evaluate the influence of systemic markers, including HbA1c, CRP, and albumin, on treatment outcomes. Methods: This randomized, double-blind controlled trial was conducted at the Centre Médical de Saint-Jean-sur-Veyle from April to June 2025. Ninety adult patients with mild-to-moderate infected DFUs were randomly assigned to either Metronidazole or SSD. Patients with severe infection, osteomyelitis, or severe ischemia were excluded. Participants received daily topical application of either 1% Metronidazole or 1% SSD gel for four weeks, alongside standard care including debridement, offloading, and glycemic control. The primary outcome was complete wound healing at 4 weeks. Secondary outcomes included wound size reduction, time to healing, and changes in infection severity scores. Subgroup analyses assessed the impact of clinical covariates on healing. Results: Among 90 participants, 86 completed the trial. The Metronidazole group had a significantly higher healing rate (86.7%) compared with the SSD group (68.9%; p = 0.011). ANCOVA showed a significant treatment effect on wound size (F = 6.89; p = 0.011). GEE analysis identified a significant time-by-treatment interaction (OR = 3.06; p = 0.002). Poor healing was associated with wound size ≥5 cm², HbA1c ≥8%, CRP ≥10 mg/L, and albumin <3.5 g/dL. Conclusions and Relevance: Metronidazole was more effective than SSD in promoting short-term wound healing in infected DFUs. It may be considered a preferred topical agent, especially in settings with high anaerobic burden and limited resources.

Java Nursing JournalVol. 3(3)
Harapan Bangsa Institute of Technology (ID), Hospital Clínico Universitario de Caracas (VE), Nuovo Ospedale San Giovanni di Dio (IT), Centre Hospitalier de Saint Jean de Dieu (FR)
Openalex Percentile: Top 63%
Diabetic Foot Ulcer Assessment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.